Abstract
Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haases “neuroleptic threshold” concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp “all-or-none” threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, individualized dose, atypical antipsychotic agents
Current Neuropharmacology
Title: Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Volume: 7 Issue: 4
Author(s): R. Miller
Affiliation:
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, individualized dose, atypical antipsychotic agents
Abstract: Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haases “neuroleptic threshold” concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp “all-or-none” threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
Export Options
About this article
Cite this article as:
Miller R., Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031184
DOI https://dx.doi.org/10.2174/157015909790031184 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design Adult Neurogenesis and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Pharmacogenomic-Guided Rational Therapeutic Drug Monitoring: Conceptual Framework and Application Platforms for Atypical Antipsychotics
Current Medicinal Chemistry Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Editorial [ Hot Topic: Drugs Targets in Parkinson's Disease:Where Are We and Where should We Go? (Guest Editor: Mark R. Cookson)]
CNS & Neurological Disorders - Drug Targets Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?
CNS & Neurological Disorders - Drug Targets Clozapine Safety, 40 Years Later
Current Drug Safety Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry